ArticleSisli Etfal Hastanesi tip bulteni2026
Approaches to Mediastinal Staging in NSCLC Among Thoracic Surgeons: A Survey Study From Türkiye.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Mediastinal lymph node staging is a critical step in the treatment algorithm for non-small cell lung cancer (NSCLC). Current guidelines define the patient groups in which invasive or minimally invasive mediastinal lymph node sampling is required during preoperative staging. This study aimed to determine the extent to which thoracic surgeons actively practicing in Türkiye adhere to these guideline recommendations and to assess the concordance between their daily clinical practices and these recommendations. Methods: A guideline-based survey, including nine case scenarios, was emailed to 417 thoracic surgeons registered with the Turkish Thoracic Surgery Association. The survey collected data on participants' demographic characteristics, institutional profiles, and approaches to each clinical scenario. Responses were analyzed for concordance with guideline recommendations. Results: The survey response rate was 29.2% (n=122). A total of 48.3% of the participants possessed an academic title, and 77.8% were employed at training and research or university hospitals. In scenarios involving a radiologically positive, single, non-bulky N2 lymph node, 85.2% of respondents indicated that invasive mediastinal staging was required by guidelines. In contrast, among patients without radiologic evidence of N2 disease, the proportion of surgeons recommending mediastinal staging was 19.7% for squamous cell carcinoma >3 cm in size and 36.9% for adenocarcinoma. For centrally located tumors, 59% of participants recommended staging. Notably, there was substantial variation in opinions regarding the necessity of invasive sampling for suspicious aortopulmonary window lymph nodes. Conclusion: Thoracic surgeons in Türkiye generally exhibit approaches to mediastinal staging that align with guideline recommendations; however, variations exist in certain subgroups. Standardization is particularly needed in the definition of central tumors, the approach to sampling aortopulmonary lymph node stations, and staging strategies based on histologic tumor type. These findings highlight the importance of educational and awareness initiatives aimed at improving the integration of guideline recommendations into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.